CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 124 enrolled
Drug / intervention
PPV23biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02515240
NCT02515240Early Ph 1Completed
CompareCT.gov

Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

University of Toledo Health Science Campus·interventional·Posted Aug 4, 2015·Updated Aug 7, 2015

In Brief

A Early Phase 1 clinical trial evaluating PPV23 for Pneumococcal Infection. Completed, enrolled 124 participants across 1 site.

Detailed Summary

The purpose of the study. To characterize the immune response to the pneumococcal vaccine in HIV positive individuals and to dissect the most appropriate timing and frequency of vaccination.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Infection
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Early Ph 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedAug 4, 2015
Enrollment StartJul 1, 2010
Primary CompletionJun 1, 2014
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 10.9 years ago

Interventions

PPV23biological

23 valent pneumococcal polysaccharide vaccine in Healthy adults.